Exendin-3 is a peptide derived from Gila monster venom and acts as a potent antagonist of the GLP-1 receptor. It is primarily used in research settings to investigate the role of GLP-1 signaling in glucose metabolism, insulin secretion, and appetite regulation. By competitively binding to and blocking the GLP-1 receptor, Exendin-3 serves as a valuable tool for elucidating the mechanisms underlying GLP-1 receptor agonist therapies, which are crucial for treating type 2 diabetes. It also aids in studying metabolic disorders, such as the effects on blood sugar control and potential implications for weight management. Additionally, Exendin-3 functions as a reference compound in preclinical studies for developing novel therapeutic agents targeting the GLP-1 pathway.